



# An overview of COVID-19 related to fungal infections: what do we know after the first year of pandemic?

R. G. Vitale<sup>1,2</sup> · J. Afeltra<sup>2</sup> · S. Seyedmousavi<sup>3</sup> · S. L. Giudicessi<sup>4,5</sup> · S. M. Romero<sup>1,6</sup>

Received: 11 September 2021 / Accepted: 1 February 2022 / Published online: 21 March 2022  
© The Author(s) under exclusive licence to Sociedade Brasileira de Microbiologia 2022

## Abstract

In 2019, severe acute respiratory syndrome caused by CoV-2 virus became a pandemic worldwide, being the fast spread of the disease due to the movement of infected people from one country to another, from one continent to another, or within the same country. Associated comorbidities are important factors that predispose to any fungal coinfections. Because of the importance of fungal infections in COVID-19 patients, the aim of this work was to collect data of the more encountered mycoses related to patients undergoing this disease. Aspergillosis was the first COVID-19-related fungal infection reported, being *A. fumigatus* the most frequent species for CAPA. Other fungal infections related include mainly candidiasis and mucormycosis, being *Rhizopus* spp. the more prevalent species found. Influenza-associated pulmonary aspergillosis is well documented; thus, similar complications are expected in severe forms of COVID-19 pneumonia. Therefore, in patients with COVID-19, it is important to take special attention to the surveillance and suspicion of fungal coinfections that might worsen the patient's prognosis.

**Keywords** Associated pulmonary aspergillosis (CAPA) · *Aspergillus* · *Candida* · Non-*Candida* yeasts · Mucormycosis · Pneumonia

## Introduction

In 2019 in Wuhan, China, cases of unexpected pneumonia have emerged. The etiological agent of the disease that causes severe acute respiratory syndrome (SARS) is a virus belonging to Coronaviridae family, named coronavirus (CoV-2) [1]. The first was reported in 2002 (SARS-CoV) in China and in the Middle East, Saudi Arabia in 2012, (MERS)-CoV. Thus far, SARS-CoV-2 has become a pandemic worldwide, and until now (June 23rd 2021) over 179 million of infected people and over 3 million deaths have been reported representing an obit percentage of 2.1% [2]. The rapid spread of coronavirus disease was largely due to the movement by traveling of infected people from one country to another, from one continent to another, or within the same country.

Overall, the disease pattern ranged from asymptomatic, mild flu-like to severe respiratory distress. Associated comorbidities such diabetes, chronic obstructive pulmonary disease, immunocompromised conditions like corticosteroid, interleukin inhibitors or broad-spectrum antibiotic therapy, mechanical ventilation, long-term stay in intensive care unit stay, severe lung tissue damage, acute respiratory distress

---

Responsible Editor: Carlos Pelleschi Taborda

✉ R. G. Vitale  
rvitale@conicet.gov.ar

<sup>1</sup> Consejo Nacional de Investigaciones Científicas Y Tecnológicas (CONICET), Buenos Aires, Argentina

<sup>2</sup> Unidad de Parasitología. Sector Micología. Hospital J.M. Ramos Mejía, Buenos Aires, Argentina

<sup>3</sup> Microbiology Service, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA

<sup>4</sup> Facultad de Farmacia Y Bioquímica, Cátedra de Biotecnología, Universidad de Buenos Aires (UBA), Buenos Aires, Argentina

<sup>5</sup> Instituto de Nanobiotecnología (NANOBIOTEC), CONICET-UBA, Buenos Aires, Argentina

<sup>6</sup> Instituto Multidisciplinario de Biología Vegetal (IMBIV), CONICET, FCEfYN, Universidad Nacional de Córdoba, Córdoba, Argentina

syndrome, use of catheters, immunological dysfunction, immune dysregulation characterized by decreased T cells including CD4 and CD8 cells, alveolar macrophages activity disturbed, cytokine storm, and lymphocytopenia are often seen [3–6]. Tomography findings are in mainly consisting of ground-glass opacities, nodular infiltrates and consolidations, bullous emphysema, interstitial change, halo sign, and reverse halo sign similar to what we see in patients with mucormycosis [7–9]. Clinical symptoms including cough, fever, dyspnea, and/or respiratory insufficiency are observed among many others [10].

These are indeed predisposing for any fungal coinfection, such as invasive aspergillosis (IA), disseminated candidiasis, endemic mycoses, phaeohyphomycosis, mucormycosis, or fusariosis, among others, even in the absence of classical well-defined host factors [6, 10, 11]. Prolonged use of corticosteroids is considered a risk factor for invasive fungal diseases [12]. The relation between COVID-19 and aspergillosis is known as CAPA (COVID-19-associated pulmonary aspergillosis). The criteria to classify patients with CAPA vary from those with risk factors for an IPA (invasive pulmonary aspergillosis), as considered by the EORTC [13], or those with other factors such as diabetes, obesity, or hypertension. Criteria based on AspICU algorithm [14] were also applied. Recently, a case definition for IAPA (influenza-associated pulmonary aspergillosis) was proposed by an expert panel to classify patients with CAPA, classified as putative aspergillosis rather than probable or proven [6]. In the IAPA case definition, host factors are not used because IAPA may develop in any patient with severe influenza. The European Society for Clinical Microbiology and International Society of Human and Animal Mycology recently published guidance to identify proven, probable, and possible CAPA [15]. Regardless of the definition, it is difficult to distinguish between infection and colonization.

It was reported that 14–30% of hospitalized patients diagnosed with COVID-19 develop a severe respiratory failure requiring intensive care admission. Invasive aspergillosis appeared at a range from 11 to 21 days after the onset of COVID-19 and affected up to 30% of intubated patients [16–18]. Some authors pointed to a mortality rate ranging from 15 to 30%, with less survival in patients with CAPA, compared with those without [1, 19–24]. The same trend has been previously observed for influenza-related aspergillosis [25].

In general serum galactomannan (GM) is negative, whereas bronchoalveolar lavage (BAL) GM antigen is reported positive at a percentage of 77.8, being hypothesized that patients have an airway invasive infection rather blood vessels invasion to cause release of galactomannan. Thus, wherever possible BAL GM should be performed, since it is more sensitive than in serum. However, due the high aerosolized risk, this procedure is avoided in COVID-19 patients,

and tracheal secretions, for instance, are preferred [6, 15, 20, 26]. In one study, it was observed that *Aspergillus* tests from COVID-19 patients were similar to those with pneumococcal pneumonia but lower than those with influenza. Thus, it was concluded that in ICU, the specificity of tests is low and tests like pan-fungal B-D glucan should not be used, advising that a positive test for *Aspergillus* in COVID-19 should be interpreted with caution [27].

COVID-19-associated mucormycosis will be further discussed. This is an infection that is worldwide distributed and has no predilection for a particular country. The large number of reported cases from India is link to possess a high burden with 77 million people with diabetes and another 36.5 million with prediabetes which are a high-risk condition, worsen, if is being uncontrolled, for suffering, particularly, rhino-orbital-cerebral mucormycosis [28, 29].

Treatment with interleukin inhibitors or tocilizumab (monoclonal antibody), which was used as therapy in COVID patients [30, 31], could also potentially increase the risk of other fungal infections, such those, among others, caused by *Candida* spp., *Histoplasma* spp., or *Pneumocystis jirovecii* [32]. Candidemia has been reported in 2.5–6.9% of COVID-19 patients in the ICU, mainly catheter-related infections and often with unfavorable outcomes [33, 34].

Considering all, the objective of this work was to collect data on the more encountered mycoses related to patients undergoing COVID-19. Although there are reviews related to this topic, all are, in general, treated separately. Thus, an updated data considering this information altogether can be found in this single review.

## Methods

We searched in Pub Med and Google Scholar database for eligible studies published until May 31th 2021 for COVID-19-related fungal infections, using the key words “COVID-19” AND, “CAPA,” “COVID-19” AND “fungal infections,” “COVID-19 pneumonia,” “COVID-19” AND “*Candida*” OR candidiasis, “COVID-19” AND “*Aspergillus*” OR aspergillosis, “COVID-19” AND “Mucormycosis” OR Post “COVID-19” fungal infections, “COVID-19” AND “*Cryptococcus*,” “COVID-19” AND “*Pneumocystis*,” “COVID-19” AND “*Histoplasma*” OR Histoplasmosis OR endemic mycosis. A total of 160 articles were identified through the initial database search. We excluded 32 articles including four reviews, two research letters, and the remain ones for lack of the information we needed or publications that did not report primary data. After the removal of duplicated items and screening based on title and abstract, 134 articles were assessed for eligibility. Sixty-three were related to COVID-19 and invasive pulmonary aspergillosis and definitions of probable, proven, or putative according with

the author definition criteria selection, including 36 articles of clinical case description of CAPA related. Thirty-seven publications were related to cases of mucormycosis and twenty-six to other fungal infections, including candidiasis, yeast non-*Candida* infections, pneumocystosis, and endemic mycosis. We collected data on epidemiology (age, gender, comorbidities), diagnostic methods, fungi isolated, antifungal indicated therapy, and clinical outcomes that are presented in the corresponding tables. We restricted our search to works published in the English language.

## Results

Overall, 178 cases of CAPA were published. Mortality was reported in 88 cases; survivors in 80 and 10 were not specified. The main comorbidities reported were DBT, ATH, obesity, and COPD. A total of 163 *Aspergillus* species were recovered distributed as follows: *A. fumigatus* (130), following by *A. flavus* (15), *A. niger* (5), *A. terreus* (4), *A. nidulans* (2,) and one strain of *A. ochraceus*, *A. calidoustus*, *A. awamorii*, *A. citrinoterreus*, and *A. penicilloides*. *A. fumigatus* was generally susceptible to all drugs, except in 3 reports in which the TR34L98H resistance mutation in the *cyp51A* gene was found, associated with azole resistant [35–37]. Voriconazole was the drug most used, following by amphotericin. All data is detailed in Table 1.

Mucormycosis reported cases were 158, mainly related to uncontrolled diabetes. The isolation from different samples includes *Mucor* spp. (4), *Rhizopus* spp. (16), *R. oryzae* (4), *R. azygosporus* (1), *R. arrhizus* (1), *R. microsporus* (4) *Lichtheimia* spp. (2), and *L. ramosa* (1). In cases diagnosed by histology only or those from which no isolation from culture was available, it was named as mucormycosis or Mucorales (125). Forty-eight deaths and eighty-two survivors were reported. Amphotericin liposomal formulation and deoxycholate were the most antifungal drugs used. All data is detailed in Table 2.

Fungemia due to *Candida* species was reported in 149 cases. The mortality was high, but not accurate percentage could be calculated, due non-reported data in 17 cases. Forty-four patients died and 23 survived. The most frequent species isolated from blood cultures were *C. albicans* (64), *C. auris* (51), *C. glabrata* (17), *C. tropicalis* (9), *C. parapsilosis* (6), *C. dubliniensis* (6), *C. orthopsilosis* (1), and *C. krusei* (renamed as *Pichia kudriavzevii*) (2). Non-*Candida* yeasts seen were *Trichosporon asahii* (6), *Saccharomyces cerevisiae* (2), *Rhodotorula mucilaginosa* (1), and *C. neoformans* (2). Histoplasmosis, coccidioidomycosis and paracoccidioidomycosis cases were 4, 2, and, 1, respectively. *P. jirovecii* was reported in two cases. All data is detailed in Table 3.

Only one case of pulmonary fusariosis classified as putative, due by *F. proliferatum* in an immunocompetent patient, was reported [112]. There are six reports in which mix isolations were described. One describes a pulmonary mucormycosis diagnosed by biopsy, in which from bronchoalveolar lavage *A. flavus*, *A. niger*, *C. albicans*, *C. glabrata*, and *C. krusei* were found [113]. In another study, *R. arrhizus* plus *A. fumigatus* were isolated from a lung of a patient suffering from COVID-19 [114]. In a patient with a history of pulmonary embolism treated with corticosteroids, *R. microsporus* plus *A. fumigatus* were found [42]. In one patient with lymphoma, *R. microsporus* plus *A. fumigatus* were isolated from bronchoalveolar lavage [115]. Other report showed in a patient with diabetes and leukemia, *A. fumigatus* isolated from BAL, and after some days, isolation of *R. microsporus* was detected, and in other patient with no underlying disease, treated with corticosteroids, *A. fumigatus* was first isolated and days after *L. ramosa* [81]. Other report of fatal COVID-19-associated pulmonary aspergillosis described a mix fungi isolation from respiratory tract secretions. *A. niger* plus *C. albicans* were isolated from a patient with diabetes, hepatitis B, and hypertension, whereas *A. terreus* plus *C. albicans* were isolated from an otherwise healthy patient [116].

## Discussion

The use of steroids, such as dexamethasone to modulate immune-mediated organ damage, interleukin inhibitors, and broad-spectrum antibiotics for the management of COVID-19, could exacerbate preexisting comorbidities and enhance the chances of new onset of fungal infections as was above discussed. Due to the high incidence of influenza-associated pulmonary aspergillosis, it seems natural to expect similar complications in severe forms of COVID-19 pneumonia. The incidence of fungal infections in SARS 2003 was 14.8–33% and the mortality rate 25–73.7% [117]. Besides, reports of severe influenza pneumonia complicated by fungal infections were published [118].

It is important to mention that the development of any fungal coinfection is highly expected in colonized patients, given the characteristics of the coronavirus disease. Therefore, taking into consideration, previous risk factors seem necessary, indicating whether coinfections might worsen the patient's prognostic values. Mortality in patients with COVID-19 and CAPA has been seen to increase compared to COVID-19 patients without CAPA [19]. The high mortality in CAPA patients could be related with critically ill COVID-19 individuals that require mechanical ventilation, who were mostly elderly and had significant co-existing chronic comorbidities [116].

**Table 1** *Aspergillus* species infections associated with COVID-19. According with the report, CAPA was defined as proven, probable, or putative

Species (n° Isolates)	Age range	Diagnosis	UD reported	Country	ATFT	Patient (n)	Gender	Outcome	Ref
<i>A. flavus</i> (1)	85	TS culture +. Serum GM 1.4	ATH	Argentina	AND, VCZ	1 M	M	Died	38
<i>A. flavus</i> (1)	80	TS culture +	Thyroid cancer removed	France	VCZ, ISA	1 M	M	Died	39
<i>A. flavus</i> (1)	70	LB culture +	None	Iran	VCZ	1 M	M	Died	40
<i>A. fumigatus</i> (3)	23–69	Serum GM 0.9–2.1 (5/5). TS culture + (2/5). Sputum culture + (1/5). TS GM 0.2–4.2 (3/5). Serum ALFD + (2/5)	AML, ATH (1) DBT (2)	Argentina	AMB 1/5 VCZ 4/5	4 M/1 F	M/F	Died 1/5 Alive 4/5	41
<i>A. fumigatus</i> (1)	73	Serum GM and LF: + Nested PCR +	PE. Thrombo phlebitis	Argentina	AMB VCZ	1 M	M	Alive	42
<i>A. fumigatus</i> (1)	66	TS culture +	None	Australia	VCZ	1 F	F	Alive	26
<i>A. fumigatus</i> (1)	70	TS culture + ALFD TS +. Serum GM: NG BG: NG	COPD. DBT. CKD. ATH. Obesity	Austria	VCZ	1 M	M	Died	43
<i>A. fumigatus</i> (5) <i>A. flavus</i> (1)	56–77	BAL and ETA culture +. GM 0.6–2.6. Serum GM: 0.1–0.8	CD. CT. HIV. AML. ATH. CKD	Belgium	VCZ ISA	7 M	M	Died 4/7 Alive 3/7	44
<i>A. fumigatus</i> (8)	53–73	BAL culture + (4/8) Sputum culture + (4/8)	Obesity. ATH (7). DBT (2). COPD (2). CKD (2)	China	NR	8 M	M	NR	1
<i>A. fumigatus</i> (1)	46	Sputum culture +	DBT. ATH	China	VCZ	1 M	M	Alive	45
<i>A. fumigatus</i> (2)	53–63	Culture TS +. Serum GM 0.1–1.1. BAL GM 8.2. TS GM 2.2	ATH. Asthma	Denmark	VCZ	2 F	F	Died 2/2	46
<i>A. fumigatus</i> (7)	43–77	BAL culture + (7/9). BAL GM 0.03–3.9. Serum GM 0.03–0.51	ATH (7). IHD (2). DBT (1). Obesity (3). Asthma (1). None (1)	France	VCZ 1 CAS 1 None 7/9	5 M/4 F	M/F	Died 4/9 Alive 5/9	47
<i>A. fumigatus</i> (1)	74	TS culture + Serum GM and BG: NG	MS. ATH	France	None	1 M	M	Died	48
<i>A. fumigatus</i> (15) <i>A. niger</i> (1) <i>A. calidoustus</i> (1)	44–86	BAL culture + BAL GM 0.07–3.4 (8/19)	ATH (7). COPD (4). DBT (7). Asthma (4). HIV (1). None (1). TB (2)	France	VCZ 9	15 M/4 F	M/F	Died 7/19 Alive 12/19	49
<i>A. fumigatus</i> (1) (azoles R)	56	TS culture + Serum GM and BG: NG	Obesity. DBT. ATH	France	None	1 M	M	Died	37
<i>A. fumigatus</i> (2)	70–80	BAL culture +. GM BAL GM 6.1–6.3 Serum: ≤ 0.50–1.5	Pulmonary fibrosis. None	Germany	AMBL	2 M	M	Died 2/2	50
<i>A. fumigatus</i> (3)	54–62	BAL culture + (1/5). TS culture + (2/5). BAL GM > 2.5 (3/5)	COPD (2). ATH (3) Corticosteroid therapy (3). Emphysema (1). None (2)	Germany	VCZ 2 CAS 2 ISA 1	3 M/2 F	M/F	Died 3/5 Alive 2/5	17

Table 1 (continued)

Species (n° isolates)	Age range	Diagnosis	UD reported	Country	ATFT	Patient (n)	Gender	Outcome	Ref
<i>A. fumigatus</i> (1) (azoles R)	66	TS culture + . Serum GM 1.1 Serum BG: 202 pg/ml	Obesity, DBT, ATH	Ireland	AMB	1 M		Died	35
<i>A. fumigatus</i> (1)	73	BAL culture + . Serum GM 8.6	ATH, DBT, HT, Obesity	Italy	AMBL	1 M		Died	33
<i>A. fumigatus</i> (15)	57–70	BAL culture + (19/30), BAL GM > 1 (30/30), Serum GM + (1/30)	Obesity (10), ATH (16), DBT (5), SOT (1), COPD (6)	Italy	VCZ 16/30	23 M/7 F		Died 10/30 Alive 20/30	19
<i>A. niger</i> (1)	43–83	TS culture + (2/6), BAL culture + (3/6), sputum culture + (1/6), BAL GM 1.6–4 (2/6), Serum GM 0.1–0.4 (3/6)	CODP (2), CT (3), Asthma (1), None (2)	Netherlands	VCZ + AND 5 AMBL 1	6 M		Died 4 Alive 2	21
<i>A. fumigatus</i> (1) (azoles R)	74	TS culture + TS GM: > 3, Serum BG: 1590 pg/mL	None	Netherlands	VCZ, AMBL	1 F		Died	36
<i>A. fumigatus</i> (5)	39–76	Nondirected BAL cul- ture + and GM 1.1 to > 4 (9/9)	Obesity (6), Asthma, COPD (2), ATH (3), RT (1)	Netherlands	AMB, VCZ	6 M/3 F		Died 2/9 Alive 7/9	51
<i>A. terrequis</i> (1)	59–72	TS and BAL culture + , BAL GM + (9/19), Serum GM NG	COPD, asthma (7), DBT (5)	Netherlands	NR	14 M/5 F		Died 10/19 Alive 9/19	24
<i>A. fumigatus</i> (2)	46–85	Culture + . Serum GM 0.1–0.3 (9/9)	ATH (4), DBT (8), Stroke (1)	Pakistan	AMB 2/9 VCZ 3/9 None 4/9	7 M/2 F		Died 4/9 Alive 5/9	52
<i>A. fumigatus</i> (2)	78–83	Culture BAS + , BAL GM + NG	ATH, IHD, CKD None	Spain	AMB	2 M		Alive 2/2	7
<i>A. nidulans</i> (1)	51–72	BAS culture + (8/10), BAL culture (1/10), Sputum culture + (1/10), Serum GM 0.2–1.1 and BAL GM 1.1–3.8 (2/10)	COPD (4) Obesity (2) DBT (5), MS, HIV, HT and IHD (1)	Spain	VCZ 4 AMB 5 CAS, MCF and AND 1 ISA 2 None 2	8 M/2 F		Died 7/10 Alive 1/10 NR 2/10	53
<i>A. fumigatus</i> (3)	67–73	BAL culture + . Serum GM 1.4–1.5 (3/1), One NG	None (3), Lung cancer (1)	Spain	AMB, ISA, AND	2 M/2 F		Died 1/4 Alive 3/4	54
<i>A. fumigatus</i> (6)	NR	TS culture + (1/8), BAL culture (2/8) BAS culture (7/8), BAL GM > 7 (1/8), Serum GM 0.1–1.9 (8/8), BG: 2.6–17.8 (8/8)	Obesity (4), ATH (7), COPD, SOT, CLL (1), Asthma (2)	Spain	VCZ 2/8 AMBL 2/8 ISA 4/8 None 3/8	6 M/2 F		Died 8/8	20
<i>A. citrinoterreus</i> (1)	55–66	BAS culture + Serum GM 0.7 (1/3)	ATH, obesity (2) DBT, asthma (1)	Switzerland	VCZ 3/3	3 M		Died 1/3 Alive 2/3	55

Table 1 (continued)

Species (n° isolates)	Age range	Diagnosis	UD reported	Country	ATFT	Patient (n)	Gender	Outcome	Ref
<i>A. fumigatus</i> (1)	77–82	Serum GM 0.7 (1/5), NG (2/5)	ATH, DBT, COPD, CVD (1)	USA	VCZ 3/4 CAS 1/4	5 M		Died 5/5	56
<i>A. fumigatus</i> (1)	56	TS culture +	DBT, AHT	India	VCZ	1 M		Died	57
<i>A. niger</i> (1)	73	Serum GM 4.9, BG: 84 pg/mL	DBT, ATH	Italy	VCZ	1 M		Died	58
<i>A. ochraceus</i> (1)	35	TS culture + Culture BAL + Serum GM BAL GM 2.1	None	Iran	AMBL	1 M		Died	59
<i>A. penicillioides</i> (1)	70	Autopsy, Histopathological sequencing, Serum GM 4.2	DBT, ATH, CKD	Brazil	None	1 M		Died	60
<i>A. terreus</i> (2)	66	BAL and Mini BAL culture +	None	Iran	VCZ, CAS	1 F		Died	5
<b>Resume</b>									
Total: 162	23–86	Positive cultures: 162 BAL + Mini BAL > TS > BAS GM (BAL + serum): 42 ALFD: 3 LF: 5 PCR: 2	ATH 71 > DBT 48 > Obesity 35 > COPD 26 > Asthma 19 AML 7 CKD 6 CT 5 IHD 4 HIV 3 CVD, MS, SOT, CD, HT 2 Thyroid cancer, thrombophlebitis, lung cancer, emphysema, stroke, HB: 1	20 countries	AMBL/AMB 20 AND 8 CAS 6 ISA 10 MCF 1 NR 2 VCZ 62 ATFC 6 No, ATF 19	139 M 39 F		Died 88/178 Alive 80/178 NR 10/178	

*AHT* arterial hypertension. *ALFD* *Aspergillus* lateral-flow device. *AMBL* liposomal amphotericin. *AML* acute myeloid leukemia. *AND* anidulafungin. *ATFT* antifungal treatment. *BAL* bronchoalveolar lavage. *BAS* bronchial aspirate. *BDG* 1,3-β-D-glucan. *BSAT* broad-spectrum antibiotic therapy. *CAPA* COVID-19-associated pulmonary aspergillosis. *CAS* caspofungin. *CD* cardiovascular disease. *CFA* complement fixing antibodies. *CKD* chronic kidney disease. *CLL* chronic lymphocytic leukemia. *COPD* chronic obstructive pulmonary disease. *COVID-19* coronavirus disease 2019. *CT* corticosteroid therapy. *CTS* chest tomography scan. *CVC* central venous catheter. *CVD* cardiovascular disease. *DBT* diabetes. *DVT* deep venous thrombosis. *FI* fungal infection. *GM* galactomannan. *HB* hepatitis B. *HIV* human immunodeficiency virus. *HM* hematological malignances. *HT* hyperthyroidism. *IHD* ischemic heart disease. *ISA* isavuconazole. *MCF* micafungin. *MS* myelodysplastic syndrome. *MS* myelodysplastic syndrome. *NG* negative. *NR* not reported. *NYS* nystatin. *PE* pulmonary embolism. *RF* risk factors. *RT* renal transplant. *SHF* systolic heart failure. *SOT* solid organ transplant. *TB* tuberculosis. *TMS* trimethoprim-sulfamethoxazole. *TS* tracheal secretion. *UD* underlying disease. *VCZ* voriconazole.

**Table 2** COVID-19 related to mucormycosis (CAM)

Disease or species isolated	Age range	Diagnosis	UD reported	Country	ATFT	Patient (n) Gender	Outcome	Ref
Mucormycosis (n = 1)	33	Sinus: coenocytic hyphae and culture + . Identification: NR	DBT. AHT. Asthma	USA	NR	1 F	Died	61
Mucormycosis (n = 1)	41	Sinus: coenocytic hyphae and culture + . Identification: NR	DBT	USA	AMB	1 M	Alive	62
Mucormycosis (n = 1)	60	Nasal biopsy: broad aseptate hyphae. Culture + . Identification: NR	DBT	India	AMB	1 M	Died	4
Mucormycosis (n = 2)	40–54	Sinus biopsy: broad aseptate hyphae. Culture +	None. DBT	Iran	AMB PCZ	1 F/1 M	Died 1/2 Alive 1/2	63
Mucormycosis (n = 1)	32	Paranasal tissue: broad aseptate hyphae. Identification NR	DBT	India	AMB	1 F	Alive	64
Mucormycosis (n = 1)	22	Autopsy. ID: NR	DBT	UK	NR	1 M	Died	65
Mucormycosis (n = 1)	86	Gastric ulcer sample: broad aseptate hyphae. Identification: NR	AHT	Brazil	AMBL	1 M	Died	66
Mucormycosis	20–80	Nasal endoscopic Debridement: aseptate hyphae	DBT AHT CKD	India	AMBL	20 M/11 F	Alive 28/31 Died 3/31	67
Mucormycosis <i>Rhizopus/Mucor</i> (n = NR)	23–67	TB and nasal swab +	DBT/DKA	India	AMBL	8 M/2 F	Died 4/10 Alive 6/10	68
Mucormycosis	66	Nasal swab: aseptate hyphae	DBT	India	AMBL	1 M	Alive	69
Mucormycosis	35–73	Tissue biopsy: aseptate hyphae. Identification: NR	DBT	India	AMBL	15 M/3 F	Alive 11/18 Died 7/18	28
Mucormycosis (n = 1) *	72	Guide nodule biopsy: broad aseptate hyphae. Identification: NR	DBT	India	AMBL PCZ	1 M	Alive	70
Mucormycosis (n = 23) *	NR	Maxillar and ethmoid sinus: aseptate hyphae. Identification: NR	DBT	India	AMB	15 M/8 F	Alive	71
Mucormycosis (n = 3) *	39–50	MRI suspicion of FI (3/3). Sinus tissue: hyphae	DBT	India	AMB	2 M/1 F	NR	72
Mucormycosis (n = 1) *	61	Sinus tissue: broad aseptate hyphae	None	Iran	NR	1 F	Died	73
<i>Mucor</i> spp. (n = 2)	27–68	NR	ATH. CVD and DBT. CKD	China	NR	NR	NR	23
<i>Rhizopus</i> spp. (n = 1)	47	Tissue culture +	AHT. DBT	Argentina	AMBL	1F	Alive	74
<i>Rhizopus</i> spp. (n = 1)	NR	Sinus biopsy: broad aseptate hyphae. Culture +	DBT	India	AMB	1 F	Alive	29

**Table 2** (continued)

Disease or species isolated	Age range	Diagnosis	UD reported	Country	ATFT	Patient (n) Gender	Outcome	Ref
<i>Rhizopus</i> spp. (n = 1) *	66	BAL/BAS: aseptate hyphae. Culture +	AHT	Italy	AMBL	1 M	Died	75
<i>Rhizopus</i> spp. (n = 1)	60	Sinus tissue: aseptate hyphae. Culture +	DBT/DKA Asthma. AHT	USA	AMBL AMBL + CAS	1 M	Died	76
<i>Rhizopus</i> spp. (n = 1)	49	Bronchopleural fistula: aseptate hyphae. Culture +	None	USA	AMB	1 M	Died	77
<i>R. microsporus</i> (n = 1)	55	Sputum: aseptate hyphae. Culture +	DBT	India	AMB	1 M	Alive	78
<i>R. microsporus</i> (n = 1)	53	Lung tissue post-mortem: hyaline hyphae. Culture +	AML	Austria	VCZ	1 M	Died	79
<i>R. microsporus</i> (n = 1)	60–70	Orbital pus culture (1/2) and sputum culture (1/2) +	None. DBT	Netherlands	AMBL. ISA + PCZ	2 M	Died 1/2 Alive 1/2	80
<i>R. arrhizus</i> (n = 1)								
<i>Rhizopus</i> spp. (n = 1)	36–48	Sample from eye culture + /Sample: NR	DBT	USA	AMB ISA MCF	2 M	NR	81
Mucormycosis (n = 1)								
<i>R. microsporus</i> (n = 1) *		Sternal wound cultures + . Serum GM and BG: NG	HTP. AHT. DBT. CKD	USA	AMBL + PCZ	1 M	Died	82
<i>R. oryzae</i> (n = 1)	38	Sinus biopsy: broad aseptate hyphae. Culture +	None	India	AMB	1 M	Alive	83
<i>R. oryzae</i> (n = 1)	62	Palate biopsy: aseptate hyphae. Culture +	DBT. KTR	Spain	AMB. PCZ	1 M	Alive	28
<i>R. oryzae</i> (n = 1)	44	Maxillary sinus biopsy: aseptate hyphae. Culture: NG. Tissue PCR +	DBT	Iran	AMBL PCZ	1 F	Alive	84
<i>R. oryzae</i> (n = 1) *	50	Sinus TB: broad aseptate hyphae. Culture +	DBT/AHT	Iran	AMBL	1 F	Alive	85
<i>R. azygosporus</i> (n = 1)	56	Sputum and PF: fungal elements. Tissue: broad aseptate hyphae. Culture +	CKD	USA	AMBL	1 M	Died	86
<i>Lichtheimia</i> spp. (n = 1)	24	BAL: aseptate hyphae. Culture +	DBT/DKA	Mexico	AMB	1 F	Died	87
<i>Lichtheimia ramosa</i> (n = 1)	48	Lower limb biopsy: aseptate hyphae. Culture +	KTR	Spain	AMBL ISA	1 M	Alive	88
<i>Rhizopus</i> spp. (n = 10)	46–61	Tissue culture and tissue PCR	DBT	USA	AMBL	34 M/7 F	Died 20/41 Others: NR	89
<i>Lichtheimia</i> spp. (n = 1)								
<i>Mucor</i> spp. (n = 2)								
Mucorales, unspecified (n = 28)								



**Table 2** (continued)

Disease or species isolated	Age range	Diagnosis	UD reported	Country	ATFT	Patient (n) Gender	Outcome	Ref
Total: 158	24–80	Histology 46	DBT 62	12	AMBL/	115 M	Died 48/158	
Mucormycosis 97		Positive cultures 73	AHT 5	countries	AMB 113	41F	Alive 82/158	
Mucorales 28		PCR 1	KTR 3		PCZ 5	NR 2	NR 28/158	
<i>Mucor</i> spp. 4		Fungi identified 30	DKA 2		VCZ 1			
<i>Rhizopus</i> spp. 16		Fungi non identified 125	CKD 2		ISA 2 MCF 1			
<i>R. oryzae</i> 4			AML 1		ATFC 2			
<i>R. microsporus</i> 4			None 4					
<i>R. arrhizus</i> 1			Asthma 1					
<i>R. azygosporus</i> 1								
<i>Lichtheimia</i> spp. 2								
<i>L. ramosa</i> 1								

AHT arterial hypertension. ALFD *Aspergillus* lateral-flow device. AMBL liposomal amphotericin. AML acute myeloid leukemia. AND anidulafungin. ATFT antifungal treatment. ATFc ATF combination. BAL bronchoalveolar lavage. BAS bronchial aspirate. BDG 1,3-β-D-glucan. BSAT broad-spectrum antibiotic therapy. CAM COVID-19-associated mucormycosis. CAS caspofungin. CD cardiovascular disease. CFA complement fixing antibodies. CFS spinal fluid. CKD chronic kidney disease. CLL chronic lymphocytic leukemia. COPD chronic obstructive pulmonary disease. COVID-19 coronavirus disease 2019. CT corticosteroid therapy. CTS chest tomography scan. CVC central venous catheter. CVD cardiovascular disease. DBT diabetes. DKA diabetic ketoacidosis. DVT deep venous thrombosis. GM galactomannan. HIV human immunodeficiency virus. HM hematological malignances. HT hyperthyroidism. HT hypothyroidism. HTP heart transplant patient. IHD ischemic heart disease. ISA isavuconazole. KTR kidney transplant recipient. MCF micafungin. MS myelodysplastic syndrome. MS myelodysplastic syndrome. NG negative. NR not reported. NYS nystatin. RT renal transplant. SHF systolic heart failure. SOT solid organ transplant. TB tuberculosis. TMS trimethoprim-sulfamethoxazole. TS tracheal secretion. UC ulcerative colitis. VCZ voriconazole. \*: CAM post COVID-19

Despite all this, the mortality rate is also high in non-COVID-19 patients at risk such as those with underlying neutropenia with IPA, if treatment is not initiated on time or whether the underlying disease conditions do not improve [119]. Thus, it could be reasonable that an adequate treatment for COVID-19 could have a positive impact on the absence of improvement in the evolution of IPA. Patients with COVID have chronic obstructive pulmonary disease (COPD) for which the association with aspergillosis is well known or asthma/corticoid therapy that are also known risk factors for *Aspergillus* colonization. Thus, COVID-19 might be a risk factor for aspergillosis, and the underlying pulmonary conditions may favor COVID-19-associated aspergillosis [120]. Corticosteroids treatment, as is indicated in severe COVID-19 patients, increases 3 times the risk to develop invasive fungal infections in comparison to other patients who do not receive steroids [121]. Some reports highlight the need to monitor pneumatoceles that might predispose to pneumothorax and/or cavitory lesions that could be complicated with coinfections like aspergillosis, even in the recovery phase of COVID-19 [57, 122].

Other fungal infection such as candidiasis could be expected due the aforementioned conditions that predispose for suffering a fungemia, being an important issue to be considered. Diseases such as diabetes or severe COVID-19 seem to alter the intestinal barrier function that facilitates *Candida* translocation, allowing the gut microbiota like *Candida* species, to reach the bloodstream and then disseminate systemically [123]. The estimated mortality due to invasive candidiasis is 19–40% [124], being even higher among ICU

patients, around 70% [125]. Cases of fungemia due to *C. albicans* and non albicans in COVID patients were reported in several publications. The reported cases of *C. auris* sound alarming, due the association of COVID-19 with an emerging pan-resistant yeast [34]. However, its sensitivity to antifungal agents should be studied and suspected according to the epidemiological setting. In Brazil, all *C. auris* were reported as susceptible to azoles, amphotericin, and echinocandins [95]. Some cases have been seen that appeared in colonized patients when they moved from non-COVID-19 rooms to COVID-19 rooms [97]. However, in a report by the CDC evaluating strains originating worldwide, more than 70% of the *C. auris* isolates were resistant to fluconazole. In the USA, resistance of *C. auris* isolates was about 90% for fluconazole, 30% for amphotericin B, and less than 5% for echinocandins. These proportions may include multiple isolates from the same individuals and may change as more isolates are tested [126].

No least is the report of *C. glabrata* pan-echinocandin resistant infection [92]. In Colombia, fungemia due to non-*C. albicans* was 78.94%, including *C. auris* [98]. In India, a high percentage of *C. auris* isolated from blood were resistant to fluconazole, voriconazole, flucytosine, and amphotericin [34]. In a study performed in Minas Gerais, Brazil, from 212 patients, *Candida* species were isolated in 98.2%, mostly from tracheal aspirate. The authors described a mortality rate of 90.5% and 76.3% in cases related to *Candida* non-albicans and *C. albicans*, respectively [91]. *Candida* was also related to oropharyngeal candidiasis (OPC), infecting old people with cardiovascular diseases and diabetes due

Table 3 Fungal infections non-CAPA associated to COVID-19

Strain (n isolates)	Fungal co-infection (n cases)	Age range	Diagnosis	UD reported	Country	ATFT	Patient (n) Gender	Outcome	Ref
<i>C. albicans</i> (3), <i>C. tropicalis</i> plus <i>C. albicans</i> (1), <i>C. glabrata</i> (1)	CAC (n=5)	38–76	Blood culture +	CVC. BSAT. AHT. Stroke	Oman	CAS MCF VCZ AMB	5 M	Died 3/5 Alive 2/5	90
<i>C. albicans</i> (3), <i>C. tropicalis</i> plus <i>C. krusei</i> * (1), <i>C. auris</i> (12)	CAC (n=15)	66–88	Blood culture + (15/15), Urine + (2/15)	CVC. UC. DBT. CKD. AHT	India	MCF	7 M/3 F**	Died 8/15 Alive 7/15	34
<i>C. albicans</i> (22), <i>C. tropicalis</i> (8), <i>C. glabrata</i> (3), <i>C. kefyr</i> (1)	CAC (n=49)	35–75	Blood culture + (3/49), TA (33/49), CVC (3/49), Urine (20/49), Sputum (3/49)	CD. Obesity. DBT	Brazil	MCF FCZ AMB	22 M/27 F	NR	91
<i>C. albicans</i> (2)	CAC (n=4)	27–68	NR	ATH. CVD and DBT. CKD	China	NR	NR	NR	23
<i>C. glabrata</i> (1)	CAC (n=1)	79	Blood culture +	DBT. IHD	Italy	CAS	1 M	Died	92
<i>C. albicans</i> (46), <i>C. glabrata</i> (7), <i>C. dubliniensis</i> (6), <i>C. parapsilosis</i> (3), <i>C. tropicalis</i> (2), <i>C. krusei</i> * (1)	CAC (n=65)	27–90	Oropharyngeal swab culture +	CVD. DBT. HM	Iran	FCZ CAS NYS	NR	NR	40
<i>C. glabrata</i> plus <i>C. albicans</i> (1)	CAC (n=1)	48	BAL and CVC culture + / Sac- roiliac joints biopsy culture +	AHT. Obesity	UK	FCZ	1 M	Alive	93
<i>C. auris</i> (15)	CAC (n=15)	36–82	Blood culture +	CVC. BSA	Lebanon	CAS AND AMBL	8 M/7 F	NR	94
<i>C. auris</i> (2)	CAC (n=2)	59–74	CVC culture (1/2) and blood culture (1/2) +	DVT. CKD. DBT. AHT	Brazil	AND	1 M/1 F	Alive 2/2	95
<i>C. auris</i> (4)	CAC (n=4)	NR	Blood (3/4) and urine culture (1/4) +	DBT. CVC. CKD. CVD. None	USA	NR	NR	Died	96
<i>C. auris</i> (12)	CAC (n=12)	36–66	Blood (6/12), urine (8/12) and both (2/12) cultures +	CVC. UC	Mexico	CAS AND VCZ ISA AMB	10 M/2 F	Died 8/12 Alive 4/12	97
<i>C. glabrata</i> (3), <i>C. albicans</i> (3), <i>C. tropicalis</i> (4), <i>C. parapsilosis</i> (3), <i>C. orthopsilosis</i> (1), <i>C. glabrata</i> (1), <i>Trichosporon asahii</i> (1)	CAC/CAY (n=18/1)	1–88	Blood culture +	CVC. DBT. CKD. AHT. BSAT. Cancer	Colombia	FCZ. CAS VCZ	NR	Died 12/19 Alive 6/19	98
<i>C. albicans</i> (4) <i>C. glabrata</i> (2) <i>Rhodotorula mucilaginosa</i> (1) <i>T. asahii</i> (n=5)	CAC/CAY (n=6/1) CAY	25–75 57–75	Blood culture + Blood culture +	Cancer (3). DBT (1). None (4)	Iran	FCZ	NR	Died 6/7 Alive 1/7	99
<i>Cryptococcus neoformans</i>	CAY (n=1)	NR	TB culture and CSF + Serum Ag +	DBT (2/5) Others (3/5) Prostate cancer	Brazil	VCZ (4/5)	4 M/1 F	Died (4/5)	100
<i>Cryptococcus neoformans</i>	CAY (n=1)	78	BAL culture +	AHT. COPD	USA	AMB. ISA	1 M	Died	102

**Table 3** (continued)

Strain (n isolates)	Fungal co-infection (n cases)	Age range	Diagnosis	UD reported	Country	ATFT	Patient (n) Gender	Outcome	Ref
<i>Saccharomyces cerevisiae</i>	CAY (n=1)	73–76	Blood culture +	AHT, DBT	Greece	AND FCZ	2 M	Alive	103
<i>Coccidioides immitis</i> (n=1)	CAE (n=1)	48	Serum IgM ID +	SHF	USA	FCZ	1 F	Alive	104
<i>Coccidioides</i> spp. (n=1)	CAE (n=1)	48	Serum CFA: 1/32	DBT	USA	NR	1 M	Alive	105
<i>Paracoccidioides</i> spp. (Pb) (n=1)	CAE (n=1)	19	Lymph node aspirate: multiple budding cells. Culture + . ID Ab Pb: 1/512	Malnutrition	Brazil	AMBL	1 M	NR	106
<i>Histoplasma capsulatum</i> (Hc) (n=1)	CAE (n=1)	43	Skin scarification: yeasts compatible with Hc	HIV	Argentina	AMB ITZ	1 M	Alive	107
<i>H. capsulatum</i> (n=1)	CAE (n=1)	43	Sputum: yeasts compatibles with Hc	HIV	Brazil	ITZ	1 F	Alive	108
<i>H. capsulatum</i> (n=1)	CAE (n=1)	36	Urine Gm for Hc: > 2	HIV	Argentina	AMB ITZ	1 F	Alive	109
<i>H. capsulatum</i> (n=1)	CAE (n=1)	62	Sputum: yeasts compatibles with Hc	HIV	Argentina	AMB ITZ	1 F	Alive	109
<i>H. capsulatum</i> (n=1)	CAE (n=1)	62	Urine GM: 24.7 ng/mL and serum GM 5.10 ng/mL	DBT, Asthma	USA	AMBL ISA	1 F	Alive	102
<i>Pneumocystis jirovecii</i> (Pj)	CAP (n=1)	52	CF and ID: +	HIV	Germany	TMS	1 M	Alive	110
<i>P. jirovecii</i>	CAP (n=1)	83	BAL: cysts compatible with Pj	HIV	Germany	TMS	1 M	Alive	110
<i>P. jirovecii</i>	CAP (n=1)	83	TS real time PCR + . BG: 305 pg/ml. Cystic findings on CTS	Asthma, UC, CT	USA	TMS	1 F	Alive	111

AHT arterial hypertension. ALFD *Aspergillus* lateral-flow device. AMBL liposomal amphotericin. AML acute myeloid leukemia. AND anidulafungin. ATFT antifungal treatment. BAL bronchoalveolar lavage. BAS bronchial aspirate. BDG 1,3-β-D-glucan. BSAT broad-spectrum antibiotic therapy. CAC COVID-19-associated candidiasis. CAE COVID-19-associated endemic mycosis. CAP COVID-19-associated pneumocystosis. CAS caspofungin. CAY COVID-19-associated yeasts. CD cardiovascular disease. CFA complement fixing antibodies. CFS spinal fluid. CKD chronic kidney disease. CLL chronic lymphocytic leukemia. COPD chronic obstructive pulmonary disease. COVID-19 coronavirus disease 2019. CT corticosteroid therapy. CTS chest tomography scan. CVC central venous catheter. CVD cardiovascular disease. DBT diabetes. DKA diabetic ketoacidosis. DVT deep venous thrombosis. GM galactomannan. HIV human immunodeficiency virus. HM hematological malignances. HT hyperthyroidism. HTP heart transplant patient. IHD ischemic heart disease. ISA isavuconazole. MCF micafungin. MS myelodysplastic syndrome. NG negative. NR not reported. NYS nystatin. RT renal transplant. SHF systolic heart failure. SOL solid organ transplant. TB tuberculosis. TMS trimethoprim-sulfamethoxazole. TS tracheal secretion. UC ulcerative colitis. UC urine catheter. VCZ voriconazole. \*: renamed *P. kudriavzevii*. \*\*: reported only for *C. auris*

to the weaker immune functions of these patients. CoV-2 as HIV virus produce T lymphocytes consumption [40]. Besides, elderly patients have lower activity levels of protective salivary innate defenses [127]. Fungemia by other yeasts such *Trichosporon* and *Saccharomyces cerevisiae/boulardii* was reported [98, 103]. This last is used in ICU patients as a probiotic for treatment of diarrheal disorders [128].

Moreover, it is not surprising to isolate Mucorales, since many patients with COVID-19 suffer from diabetes mellitus as their underlying disease that alters the body's immunological response enhancing fungal proliferation and diminishing the phagocytic capacity of host immune cells [129]. Besides, corticosteroids have other side effects such as blunting the action of insulin with the increment of blood glucose. This hyperglycemic effect is magnified in diabetic patients and can lead to ketoacidosis [130]. In addition, the ketone reductase enzyme in *Rhizopus* organisms allowing them to thrive in high glucose and acidic conditions, being the reason for the stimulated growth of these organisms in those patients [131]. It is known that in patients with ketoacidosis, rhino-orbital-cerebral mucormycosis can develop, regardless of whether the patient is undergoing a COVID-19 infection. Mucormycosis without concomitant COVID-19 infection has a mortality rate ranging from 40 to 80% [9]. Severe immunocompromised from untreated diabetes made the patients be susceptible to contract both mucormycosis and COVID-19 [4, 61]. In general, uncontrolled diabetes was the main risk factor [67]. The mortality rate appears to reach 100% when both diseases are associated [113]. Besides, it is very important that ophthalmologists suspect the possible orbital infarction syndrome secondary to mucormycosis in these patients [69]. In one report, loss of vision was observed in 66% and orbital exenteration in 38% of the patients analyzed [28].

However, some cases of patients with diabetes without ketosis are reported [29, 70], as well some with non-underlying condition, suggesting a COVID-19 as risk factor due to steroids or interleukin inhibitor therapies [73, 83]. It is important to note that although corticosteroid therapy helps for the treatment of the severe form of COVID, when comorbidities such as diabetes or other immunosuppression factors exist, can be harmful. Steroids can exacerbate hyperglycemia. Therefore, close monitoring hospitalized patients and after discharged should be take into account for possible complications of post-COVID-19 fungal infections such the cases of mucormycosis that have been described [70, 71, 82, 85]. Thus, diagnosis of mucormycosis requires clinical observations, images, histopathologic findings, fungal culture, and surgical debridement which seem to improve patient survival. However, no growth happens very frequently, being important to consider the proper clinical context for suspicion. The risk of *Pneumocystis* pneumonia increases significantly with severe CD4 lymphocytopenia [132]. This is

the case of HIV patients, and also this scenario occurs with COVID-19 infection. Thus, patients without other underlying factors might suffer of pneumocystosis as has been reported [111].

SARS-CoV-2 and endemic mycoses have overlapping risk factors. Coccidioidomycosis, histoplasmosis, and paracoccidioidomycosis have been reported. There is a lack of information if severity of COVID and endemic mycosis can be influenced one by the other. It is possible that the fungus stays in a latent stage and be reactivated due to coronavirus disease related to immune dysregulation. In areas where these fungi are endemic, awareness should be taken [102, 104, 107, 108].

The frequency of COVID-19 in AIDS is not higher than the frequency of COVID-19 in the general population [133, 134]. There are reported cases of COF or other infections in HIV/COVID-19-positive patients. However, we do not think it is unexpected, since patients with CD4 < 100 generally present COF to different *Candida* species, endemic diseases, or cryptococcosis. We think that these are HIV-positive patients, with low CD4s susceptible for suffering marker diseases and who were infected with COVID-19. This thought is in agreement with the favorable outcome of HIV/COVID/histoplasmosis case patients in whom not lung damage was observed and no ICU was required [108]. The course and presentation of the reported cases do not vary from those negative COVID-19. Those cases should be taken into account to indicate the appropriate treatment but might not be taken as a separate entity. Nevertheless, the true role of the SARS-CoV-2 virus in HIV patients remains to be fully elucidated.

## Conclusion

This review aimed to summarize all the main published reports of COVID-19-associated fungal infections identified by different methodologies, among which *A. fumigatus* can be considered the most prevalent species reported for CAPA. However, it is difficult to compare the different published studies since not all medical centers use the same criteria to define CAPA, reason for which is needed to find consensus on these definitions. The diagnosis is complicated because serum GM is generally negative, with BAL being the most sensitive sample, but it is difficult to perform due to the risk it represents. Cultures are not very profitable either and PCR is not always useful or available. The suspicion and searching for fungal infections, whether of yeast, hyaline, or pigmented fungi, should be taken into account to indicate the appropriate treatment and improve the patient's prognosis. In addition, it is of paramount importance to make physicians aware of the fact that invasive fungal infections might occur after patients with COVID-19 have been discharged,

particularly those with predisposing conditions, such uncontrolled diabetes related with mucormycosis. This entity has been relevant in recent days, due to the indiscriminate increase in reported cases, especially in India. Therefore, it is mandatory to establish an exhaustive patient follow-up and combine different methodologies of laboratory diagnosis, images, and clinical suspicion related to any fungal infection-COVID-19 related.

**Acknowledgements** R.G.V. and S.M.R. are grateful to Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación de Argentina (PICT-2018-03781). The work of S.S. was supported by the Intramural Research Program of the National Institutes of Health, Clinical Center, Department of Laboratory Medicine.

**Author contribution** All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Vitale RG, Romero SM, Giudicessi SL, Seyedmousavi S, and Afeltra J. The first draft of the manuscript was written by Vitale RG, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

**Availability of data and material** All data is public available.

**Code availability** Not applicable for this section.

## Declarations

**Ethics approval** Not applicable for this section.

**Consent to participate** Not applicable for this section.

**Consent for publication** Not applicable for this section.

**Conflict of interest** The authors declare no competing interests.

## References

- Wang J, Yang Q, Zhang P, Sheng J, Zhou J, Qu T (2020) Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: a retrospective case series. *Crit Care* 24:299. <https://doi.org/10.1186/s13054-020-03046-7>
- World Health Organization. <https://covid19.who.int/> [Accessed 24 June 2021]
- Du Z, Xu X, Wu Y, Wang L, Cowling BJ, Meyers LA (2020) Serial interval of COVID-19 among publicly reported confirmed cases. *Emerg Infect Dis* 26:1341–1343. <https://doi.org/10.3201/eid2606.200357>
- Mehta S, Pandey A (2020) Rhino-orbital mucormycosis associated with COVID-19. *Cureus* 12:e10726. <https://doi.org/10.7759/cureus.10726>
- Abolghasemi S, Hakamifard A, Sharifynia S, Pourabdollah Toutkaboni M, Azhdari TH (2021) Fatal invasive pulmonary aspergillosis in an immunocompetent patient with COVID-19 due to *Aspergillus terreus*: a case study. *Clin Case Rep* 9:2414–2418. <https://doi.org/10.1002/ccr3.4051>
- Verweij PE, Rijnders BJA, Brüggemann RJM, Azoulay E, Bassetti M, Blot S et al (2020) Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. *Intensive Care Med* 46:1524–1535. <https://doi.org/10.1007/s00134-020-06091-6>
- García Clemente M, HermidaValverde T, Leizaola-Irigoyen O, Rodríguez AIE, Guillén MA, TelentiAsensio M et al (2021) Can SARS-CoV-2 be a risk factor for pulmonary aspergillosis? *Arch Bronconeumol* 57(Suppl1):72–3. <https://doi.org/10.1016/j.arbres.2020.06.028>
- Apostolopoulou A, Esquer Garrigos Z, Vijayvargiya P, Lerner AH, Farmakiotis D (2020) Invasive pulmonary aspergillosis in patients with SARS-CoV-2 infection: a systematic review of the literature. *Diagnostics (Basel, Switzerland)* 10:807. <https://doi.org/10.3390/diagnostics10100807>
- Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B et al (2019) Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. *Lancet Infect Dis* 19:e405–e421. [https://doi.org/10.1016/S1473-3099\(19\)30312-3](https://doi.org/10.1016/S1473-3099(19)30312-3)
- Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H et al (2020) Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med* 8:475–481. [https://doi.org/10.1016/S2213-2600\(20\)30079-5](https://doi.org/10.1016/S2213-2600(20)30079-5)
- Salehi M, Khajavirad N, Seifi A, Salahshour F, Jahanbin B, Kazemizadeh H et al (2021) Proven *Aspergillus flavus* pulmonary aspergillosis in a COVID-19 patient: a case report and review of the literature. *Mycoses* 00:1–8. <https://doi.org/10.1111/myc.13255>
- Arastehfar A, Carvalho A, van de Veerndonk FL, Jenks JD, Koehler P, Krause R et al (2020) COVID-19 associated pulmonary aspergillosis (CAPA)-from immunology to treatment. *J Fungi* 6:91. <https://doi.org/10.3390/jof6020091>
- Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE et al (2020) Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. *Clin Infect Dis* 71:1367–1376. <https://doi.org/10.1093/cid/ciz1008>
- Blot SI, Taccone FS, Van den Abeele A-M, Bulpa P, Meersseman W, Brusselaers N et al (2012) A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. *Am J Respir Crit Care Med* 186:56–64. <https://doi.org/10.1164/rccm.201111-1978OC>
- Koehler P, Bassetti M, Chakrabarti A, Chen SCA, Lopes Colombo A, Hoenigl M et al (2020) Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. *Lancet Infect Dis* 21:149–242. [https://doi.org/10.1016/S1473-3099\(20\)30847-1](https://doi.org/10.1016/S1473-3099(20)30847-1)
- Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G et al (2020) Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. *JAMA Intern Med* 180:1345–1355. <https://doi.org/10.1001/jamainternmed.2020.3539>
- Koehler P, Cornely OA, Böttiger BW, Duse F, Eichenauer DA, Fuchs F et al (2020) COVID-19 associated pulmonary aspergillosis. *Mycoses* 63:528–534. <https://doi.org/10.1111/myc.13096>
- Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW et al (2020) Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. *JAMA* 323:2052–2059. <https://doi.org/10.1001/jama.2020.6775>
- Bartoletti M, Pascale R, Cricca M, Rinaldi M, Maccaro A, Buscini L, et al. Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study. *Clin*



- Infect Dis 2020; published online July 28. <https://doi.org/10.1093/cid/ciaa1065>
20. Machado M, Valerio M, Álvarez-Uría A, Olmedo M, Veintimilla C, Padilla B et al (2021) Invasive pulmonary aspergillosis in the COVID-19 era: an expected new entity. *Mycoses* 64:132–143. <https://doi.org/10.1111/myc.13213>
  21. van Arkel ALE, Rijpstra TA, Belderbos HNA, van Wijngaarden P, Verweij PE, Bentvelsen RG (2020) COVID-19-associated pulmonary aspergillosis. *Am J Respir Crit Care Med* 202:132–135. <https://doi.org/10.1164/rccm.202004-1038LE>
  22. Gangneux J-P, Reizine F, Guegan H, Pinceaux K, Le Balch P, Prat E et al (2020) Is the COVID-19 pandemic a good time to include *Aspergillus* molecular detection to categorize aspergillosis in ICU patients? A Monocentric Experience *J Fungi* 6:105. <https://doi.org/10.3390/jof6030105>
  23. He Y, Li W, Wang Z, Chen H, Tian L, Liu D (2020) Nosocomial infection among patients with COVID-19: a retrospective data analysis of 918 cases from a single center in Wuhan. *China Infect Control Hosp Epidemiol* 41:982–983. <https://doi.org/10.1017/ice.2020.126>
  24. van Grootveld R, van Paassen J, de Boer MGJ, Claas ECJ, Kuijper EJ, van der Beek MT et al (2021) Systematic screening for COVID-19 associated invasive aspergillosis in ICU patients by culture and PCR on tracheal aspirate. *Mycoses* 64:641–650. <https://doi.org/10.1111/myc.13259>
  25. Schauwvlieghe AFAD, Rijnders BJA, Philips N, Verwijs R, Vanderbeke L, Van Tienen C, Lagrou K et al (2018) Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. *Lancet Respir Med* 6:782–792. [https://doi.org/10.1016/S2213-2600\(18\)30274-1](https://doi.org/10.1016/S2213-2600(18)30274-1)
  26. Sharma A, Hofmeyr A, Bansal A, Thakkar D, Lam L, Harrington Z et al (2021) COVID-19 associated pulmonary aspergillosis (CAPA): an Australian case report. *Med Mycol Case Rep* 31:6–10. <https://doi.org/10.1016/j.mmcr.2020.06.002>
  27. Yusuf E, Vonk A, van den Akker JPC, Bode L, Sips GJ, Rijnders BJA et al (2021) Frequency of positive *Aspergillus* tests in COVID-19 patients in comparison to other patients with pulmonary infections admitted to the Intensive Care Unit. *J Clin Microbiol* 59:e02278–e2320. <https://doi.org/10.1128/JCM.02278-20>
  28. Moorthy A, Gaikwad R, Krishna S, Hegde R, Tripathi KK, Kale PG, et al. (2021) SARS-CoV-2, uncontrolled diabetes and corticosteroids-an unholy trinity in invasive fungal infections of the maxillofacial region? A retrospective, multi-centric analysis. *J Maxillofac Oral Surg*:1–8. <https://doi.org/10.1007/s12663-021-01532-1>
  29. Revannavar SM, Supriya PS, Samaga L, Vineeth VK (2021) COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world? *BMJ Case Rep* 14:e241663. <https://doi.org/10.1136/bcr-2021-241663>
  30. Uchida T, Okamoto M, Fujikawa K, Yoshikawa D, Mizokami A, Mihara T et al (2019) Gastric mucormycosis complicated by a gastropleural fistula: a case report and review of the literature. *Medicine (Baltimore)* 98:e18142. <https://doi.org/10.1097/MD.00000000000018142>
  31. Honda H, Kida H, Yoshida M, Fujii M, Ihara S, Goya S et al (2011) Recurrent allergic bronchopulmonary aspergillosis in a patient with rheumatoid arthritis treated with etanercept and tocilizumab. *Mod Rheumatol* 21:660–664. <https://doi.org/10.1007/s10165-011-0449-0>
  32. Vallabhaneni S, Chiller TM (2016) Fungal infections and new biologic therapies. *Curr Rheumatol Rep* 18:29. <https://doi.org/10.1007/s11926-016-0572-1>
  33. Antinori S, Bonazzetti C, Gubertini G, Capetti A, Pagani C, Morena V et al (2020) Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia? *Autoimmun Rev* 19:102564. <https://doi.org/10.1016/j.autrev.2020.102564>
  34. Chowdhary A, Tarai B, Singh A, Sharma A (2020) Multidrug-resistant *Candida auris* infections in critically ill coronavirus disease patients, India, April–July 2020. *Emerg Infect Dis* 26:2694–2696. <https://doi.org/10.3201/eid2611.203504>
  35. Mohamed A, Hassan T, Trzos-Grzybowska M, Thomas J, Quinn A, O'Sullivan M et al (2021) Multi-triazole-resistant *Aspergillus fumigatus* and SARS-CoV-2 co-infection: A lethal combination. *Med Mycol Case Rep* 31:11–14. <https://doi.org/10.1016/j.mmcr.2020.06.005>
  36. Meijer EFJ, Dofferhoff ASM, Hoiting O, Buil JB, Meis JF (2020) Azole-resistant COVID-19-associated pulmonary aspergillosis in an immunocompetent host: a case report. *J Fungi* 6:79. <https://doi.org/10.3390/jof6020079>
  37. Ghelfenstein-Ferreira T, Saade A, Alanio A, Bretagne S, Araujo de Castro R, Hamane S et al (2021) Recovery of a triazole-resistant *Aspergillus fumigatus* in respiratory specimen of COVID-19 patient in ICU - A case report. *Med Mycol Case Rep* 31:15–8. <https://doi.org/10.1016/j.mmcr.2020.06.006>
  38. Fernandez NB, Caceres DH, Beer KD, Irrazabal C, Delgado G, Farias L et al (2021) Ventilator-associated pneumonia involving *Aspergillus flavus* in a patient with coronavirus disease 2019 (COVID-19) from Argentina. *Med Mycol Case Rep* 31:19–23. <https://doi.org/10.1016/j.mmcr.2020.07.001>
  39. Lescure F-X, Bouadma L, Nguyen D, Parisey M, Wicky P-H, Behillil S et al (2020) Clinical and virological data of the first cases of COVID-19 in Europe: a case series. *Lancet Infect Dis* 20:697–706. [https://doi.org/10.1016/S1473-3099\(20\)30200-0](https://doi.org/10.1016/S1473-3099(20)30200-0)
  40. Salehi M, Ahmadikia K, Mahmoudi S, Kalantari S, Jamalimoghadamshahkhalil S, Izadi A et al (2020) Oropharyngeal candidiasis in hospitalised COVID-19 patients from Iran: species identification and antifungal susceptibility pattern. *Mycoses* 63:771–778. <https://doi.org/10.1111/myc.13137>
  41. Benedetti MF, Alava KH, Sagardia J, Corella Cadena R, Laplume D, Capece P et al (2021) COVID-19 associated pulmonary aspergillosis in ICU patients: report of five cases from Argentina. *Med Mycol Case Rep* 31:24–28. <https://doi.org/10.1016/j.mmcr.2020.11.003>
  42. Sasoni N, Rodriguez Müller M, Posse G, González J, Leonardelli F, Garcia-Effron G (2021) SARS-CoV-2 and *Aspergillus* section Fumigati coinfection in an immunocompetent patient treated with corticosteroids. *Rev Iberoam Micol* 38:16–18. <https://doi.org/10.1016/j.riam.2020.11.001>
  43. Prattes J, Valentin T, Hoenigl M, Talakic E, Reisinger AC, Eller P (2021) Invasive pulmonary aspergillosis complicating COVID-19 in the ICU - a case report. *Med Mycol Case Rep* 31:2–5. <https://doi.org/10.1016/j.mmcr.2020.05.001>
  44. Rutsaert L, Steinfort N, Van Hunsel T, Bomans P, Naesens R, Mertes H et al (2020) COVID-19-associated invasive pulmonary aspergillosis. *Ann Intensive Care* 10:71. <https://doi.org/10.1186/s13613-020-00686-4>
  45. Wu S, Yang S, Chen R, Chen H, Xu Y, Lin B (2020) Dynamic immune response profiles and recovery of a covid-19 patient with coinfection of *Aspergillus fumigatus* and other baseline diseases: A case report. *OMICS* 24:615–618. <https://doi.org/10.1089/omi.2020.0110>
  46. Helleberg M, Steensen M, Arendrup MC (2021) Invasive aspergillosis in patients with severe COVID-19 pneumonia. *Clin Microbiol Infect* 27:147–148. <https://doi.org/10.1016/j.cmi.2020.07.047>
  47. Alanio A, Dellièrre S, Fodil S, Bretagne S, Mégarbane B (2020) Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. *Lancet Respir Med* 8:e48–e49. [https://doi.org/10.1016/S2213-2600\(20\)30237-X](https://doi.org/10.1016/S2213-2600(20)30237-X)

48. Blaize M, Mayaux J, Nabet C, Lampros A, Marcelin A-G, Thellier M et al (2020) Fatal invasive aspergillosis and coronavirus disease in an immunocompetent patient. *Emerg Infect Dis* 26:1636–1637. <https://doi.org/10.3201/eid2607.201603>
49. Dupont D, Menotti J, Turc J, Miossec C, Wallet F, Richard J-C et al (2021) Pulmonary aspergillosis in critically ill patients with coronavirus disease 2019 (COVID-19). *Med Mycol* 59:110–114. <https://doi.org/10.1093/mmy/myaa078>
50. Lahmer T, Kriescher S, Herner A, Rothe K, Spinner CD, Schneider J et al (2021) Invasive pulmonary aspergillosis in critically ill patients with severe COVID-19 pneumonia: results from the prospective AspCOVID-19 study. *PLoS ONE* 16:e0238825. <https://doi.org/10.1371/journal.pone.0238825>
51. Van Biesen S, Kwa D, Bosman RJ, Juffermans NP (2020) Detection of invasive pulmonary aspergillosis in covid-19 with non-directed bronchoalveolar lavage. *Am J Respir Crit Care Med* 202:1171–1173. <https://doi.org/10.1164/rccm.202005-2018LE>
52. Nasir N, Farooqi J, Mahmood SF, Jabeen K (2020) COVID-19-associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: an observational study from Pakistan. *Mycoses* 63:766–770. <https://doi.org/10.1111/myc.13135>
53. Falces-Romero I, Ruiz-Bastián M, Díaz-Pollán B, Maseda E, García-Rodríguez J (2020) SARS-CoV-2 Working Group. Isolation of *Aspergillus* spp. in respiratory samples of patients with COVID-19 in a Spanish Tertiary Care Hospital. *Mycoses* 63:1144–48. <https://doi.org/10.1111/myc.13155>
54. Martín CS, Martíne EM, Pellicer RG, Ibáñez RA, González EM, Pitarch JVL. Invasive pulmonary aspergillosis in patients with acute respiratory syndrome by COVID-19. *Rev Esp Anestesiol Reanim* 2021; published online April 20. <https://doi.org/10.1016/j.redar.2021.02.012>
55. Lamoth F, Glampedakis E, Boillat-Blanco N, Oddo M, Pagani J-L (2020) Incidence of invasive pulmonary aspergillosis among critically ill COVID-19 patients. *Clin Microbiol Infect* 26:1706–1708. <https://doi.org/10.1016/j.cmi.2020.07.010>
56. Mitaka H, Perlman DC, Javaid W, Salomon N (2020) Putative invasive pulmonary aspergillosis in critically ill patients with COVID-19: an observational study from New York City. *Mycoses* 63:1368–1372. <https://doi.org/10.1111/myc.13185>
57. Mallappa M, Rangappa P, Jacob I, Helavar RV, Rao K (2021) A case report of coronavirus disease-19-associated pulmonary aspergillosis and pneumothorax. *Indian J Case Reports* 7:146–148. <https://doi.org/10.32677/IJCR.2021.v07.i04.007>
58. Trovato L, Calvo M, Migliorisi G, Astuto M, Oliveri F, Oliveri S (2021) Fatal VAP-related pulmonary aspergillosis by *Aspergillus niger* in a positive COVID-19 patient. *Respir Med case reports* 32:101367. <https://doi.org/10.1016/j.rmcr.2021.101367>
59. Hakamifard A, Hashemi M, Fakhim H, Aboutalebian S, Hajiahmadi S, Mohammadi R (2021) Fatal disseminated aspergillosis in an immunocompetent patient with COVID-19 due to *Aspergillus ochraceus*. *J Mycol Med* 31:101124. <https://doi.org/10.1016/j.mycmed.2021.101124>
60. Santana MF, Pivoto G, Alexandre MAA, Baía-da-Silva DC, da Silva Borba MG, Almeida Val F et al (2020) Confirmed invasive pulmonary aspergillosis and COVID-19: the value of postmortem findings to support antemortem management. *Rev Soc Bras Med Trop* 53:e20200401. <https://doi.org/10.1590/0037-8682-0401-2020>
61. Werthman-Ehrenreich A (2021) Mucormycosis with orbital compartment syndrome in a patient with COVID-19. *Am J Emerg Med* 42:264.e5-264.e8. <https://doi.org/10.1016/j.ajem.2020.09.032>
62. Alekseyev K, Didenko L, Chaudhry B (2021) Rhinocerebral mucormycosis and COVID-19 pneumonia. *J Med Cases* 12:85–9. <https://doi.org/10.14740/jmc3637>
63. Veisi A, Bagheri A, Eshaghi M, Rikhtehgar MH, Rezaei Kanavi M, Farjad R. Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: a case report. *Eur J Ophthalmol* 2021:11206721211009450. <https://doi.org/10.1177/11206721211009450>
64. Saldanha M, Reddy R, Vincent MJ. Title of the article: paranasal mucormycosis in COVID-19 patient. *Indian J Otolaryngol Head Neck Surg* 2021:1–4. <https://doi.org/10.1007/s12070-021-02574-0>
65. Hanley B, Naresh KN, Roufousse C, Nicholson AG, Weir J, Cooke GS et al (2020) Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. *The Lancet Microbe* 1:e245–e253. [https://doi.org/10.1016/S2666-5247\(20\)30115-4](https://doi.org/10.1016/S2666-5247(20)30115-4)
66. do Monte Junior ES, Dos Santos MEL, Ribeiro IB, de Oliveira Luz G, Ryokababa E, Salomãohirsch B et al (2020) Rare and fatal gastrointestinal mucormycosis (Zygomycosis) in a COVID-19 patient: a case report. *Clin Endosc* 2020(53):746–9. <https://doi.org/10.5946/ce.2020.180>
67. Ravani SA, Agrawal GA, Leuva PA, Modi PH, Amin KD (2021) Rise of the phoenix: mucormycosis in COVID-19 times. *Indian J Ophthalmol* 69:1563–1568. [https://doi.org/10.4103/ijoo.IJO\\_310\\_21](https://doi.org/10.4103/ijoo.IJO_310_21)
68. Sarkar S, Gokhale T, Choudhury SS, Deb AK (2021) COVID-19 and orbital mucormycosis. *Indian J Ophthalmol* 69:1002–1004. [https://doi.org/10.4103/ijoo.IJO\\_3763\\_20](https://doi.org/10.4103/ijoo.IJO_3763_20)
69. Rao R, Shetty AP, Nagesh CP (2021) Orbital infarction syndrome secondary to rhino-orbital mucormycosis in a case of COVID-19: clinico-radiological features. *Indian J Ophthalmol* 69:1627–1630. [https://doi.org/10.4103/ijoo.IJO\\_1053\\_21](https://doi.org/10.4103/ijoo.IJO_1053_21)
70. Raghavendra Rao MV, Kumar Chennamchetty V, Adimulapu S, Patel Kola B, De Padua MCA (2021) Post-COVID pulmonary mucormycosis- a case report. *IP Indian J Immunol Respir Med* 6:62–6. <https://doi.org/10.18231/ij.ijirm.2021.014>
71. Sharma S, Grover M, Bhargava S, Samdani S, Kataria T (2021) Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. *J Laryngol Otol* 135:1–6. <https://doi.org/10.1017/S0022215121000992>
72. Deshmukh R, Upadhyay K, Patwadkar R, Patil S (2020) Mucor Mycosis in COVID-19: Case reports. *J Adv Res Med* 7:20–3. <https://doi.org/10.24321/2349.7181.202016>
73. Karimi-Galougahi M, Arastou S, Haseli S (2021) Fulminant mucormycosis complicating coronavirus disease 2019 (COVID-19). *Int Forum Allergy Rhinol* 11:1029–1030. <https://doi.org/10.1002/alr.22785>
74. Ministerio de salud de Argentina. <https://www.argentina.gob.ar/noticias/salud-informa-sobre-un-caso-notificado-de-hongo-negro-asociado-covid-19> [Accessed 22 June 2021]
75. Pasero D, Sanna S, Liperi C, Piredda D, Branca GP, Casadio L, et al. A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis. *Infection* 2020; published online Dec 17. <https://doi.org/10.1007/s15010-020-01561-x>
76. Mekonnen ZK, Ashraf DC, Jankowski T, Grob SR, Vagefi MR, Kersten RC et al (2021) Acute invasive rhino-orbital mucormycosis in a patient with COVID-19-associated acute respiratory distress syndrome. *Ophthalm Plast Reconstr Surg* 37:e40-80. <https://doi.org/10.1097/IOP.0000000000001889>
77. Placik DA, Taylor WL, Wnuk NM (2020) Bronchopleural fistula development in the setting of novel therapies for acute respiratory distress syndrome in SARS-CoV-2 pneumonia. *Radiol Case Reports* 15:2378–2381. <https://doi.org/10.1016/j.radcr.2020.09.026>
78. Garg D, Muthu V, Sehgal IS, Ramachandran R, Kaur H, Bhalla A et al (2021) Coronavirus disease (covid-19) associated mucormycosis (CAM): case report and systematic review

- of literature. *Mycopathologia* 186:289–298. <https://doi.org/10.1007/s11046-021-00528-2>
79. Zurl C, Hoeningl M, Schulz E, Hatzl S, Gorkiewicz G, Krause R et al (2021) Autopsy proven pulmonary mucormycosis due to *Rhizopus microsporus* in a critically ill COVID-19 patient with underlying hematological malignancy. *J Fungi* 7:88. <https://doi.org/10.3390/jof7020088>
  80. Buil JB, van Zanten ARH, Bentvelsen RG, Ripstra TA, Goorhuis B, van der Voort S et al (2021) Case series of four secondary mucormycosis infections in COVID-19 patients, the Netherlands, December 2020 to May 2021. *Euro Surveill* 26:2100510. <https://doi.org/10.2807/1560-7917.ES.2021.26.23.2100510>
  81. Dallalzadeh LO, Ozzello DJ, Liu CY, Kikkawa DO, Korn BS. (2021) Secondary infection with rhino-orbital cerebral mucormycosis associated with COVID-19. *Orbit*:1–4. <https://doi.org/10.1080/01676830.2021.1903044>
  82. Khatri A, Chang K-M, Berlinrut I, Wallach F (2021) Mucormycosis after coronavirus disease 2019 infection in a heart transplant recipient - case report and review of literature. *J Mycol Med* 31:101125. <https://doi.org/10.1016/j.mycmed.2021.101125>
  83. Maini A, Tomar G, Khanna D, Kini Y, Mehta H, Bhagyasree V (2021) Sino-orbital mucormycosis in a COVID-19 patient: a case report. *Int J Surg Case Rep* 82:105957. <https://doi.org/10.1016/j.ijscr.2021.105957>
  84. Ahmadikia K, Hashemi SJ, Khodavaissy S, Getso MI, Alijani N, Badali H, et al. The double-edged sword of systemic corticosteroid therapy in viral pneumonia: a case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis. *Mycoses* 2021; published online Feb 16. <https://doi.org/10.1111/myc.13256>
  85. Tabarsi P, Khalili N, Pourabdollah M, Sharifynia S, Safavi Naeini A, Ghorbani J, et al. COVID-19 associated rhinosinusitis mucormycosis due to *Rhizopus oryzae*: a rare but potentially fatal infection occurring after treatment with corticosteroids. *Res Square* 2021. <https://doi.org/10.21203/rs.3.rs-398594/v2>
  86. Kanwar A, Jordan A, Olewiler S, Wehberg K, Cortes M, Jackson BR (2021) A fatal case of *Rhizopus azygosporus* pneumonia following COVID-19. *J Fungi* 7:174. <https://doi.org/10.3390/jof7030174>
  87. Waizel-Haiat S, Guerrero-Paz JA, Sanchez-Hurtado L, Calleja-Alarcon S, Romero-Gutierrez L (2021) A case of fatal rhino-orbital mucormycosis associated with new onset diabetic ketoacidosis and COVID-19. *Cureus* 13:e13163. <https://doi.org/10.7759/cureus.13163>
  88. Arana C, Cuevas Ramirez RE, Xipell M, Casals J, Moreno A, Herrera S, et al. (2021) Mucormycosis associated with covid-19 in two kidney transplant patients. *Transpl Infect Dis*: e13652. <https://doi.org/10.1111/tid.13652>
  89. John TM, Jacob CN, Kontoyiannis DP (2021) When uncontrolled diabetes mellitus and severe COVID-19 converge: the perfect storm for mucormycosis. *J Fungi* 7:298. <https://doi.org/10.3390/jof7040298>
  90. Al-Hatmi AMS, Mohsin J, Al-Huraizi A, Khamis F (2021) COVID-19 associated invasive candidiasis. *J Infect* 82:e45–e46. <https://doi.org/10.1016/j.jinf.2020.08.005>
  91. Silva DL, Lima CM, Magalhães VC, Baltazar LM, Peres NT, Caligiorne R et al (2021) Fungal and bacterial coinfections increase mortality of severely ill COVID-19 patients. *J Hosp Infect* 2021(113):145–154. <https://doi.org/10.1016/j.jhin.2021.04.001>
  92. Posteraro B, Torelli R, Vella A, Leone PM, De Angelis G, De Carolis E et al (2020) Pan-echinocandin-resistant *Candida glabrata* bloodstream infection complicating COVID-19: a fatal case report. *J Fungi* 6:163. <https://doi.org/10.3390/jof6030163>
  93. Onac I, Ali S, Mahto A, Rutherford A, Galloway J, Nagra D (2020) EP13 A case of *Candida albicans* septic sacroiliitis complicating severe COVID-19 infection. *Rheumatol Adv Pract* 4:23. <https://doi.org/10.1093/rap/rkaa052.012>
  94. Allaw F, Kara Zahreddine N, Ibrahim A, Tannous J, Taleb H, Bizri AR et al (2021) First *Candida auris* outbreak during a COVID-19 pandemic in a tertiary-care center in Lebanon. *Pathog* 10:157. <https://doi.org/10.3390/pathogens10020157>
  95. de Almeida JN, Francisco EC, Hagen F, Brandão IB, Pereira FM, Presta Dias PH et al (2021) Emergence of *Candida auris* in Brazil in a COVID-19 intensive care unit. *J Fungi* 7:220. <https://doi.org/10.3390/jof7030220>
  96. Prestel C, Anderson E, Forsberg K, Lyman M, de Perio MA, Kuhar D et al (2021) *Candida auris* outbreak in a COVID-19 specialty care unit - Florida, July-August 2020. *MMWR Morb Mortal Wkly Rep* 70:56–57
  97. Villanueva-Lozano H, Treviño-Rangel R de J, González GM, Ramírez-Elizondo MT, Lara-Medrano R, Aleman-Bocanegra MC et al (2021) Outbreak of *Candida auris* infection in a COVID-19 hospital in Mexico. *Clin Microbiol Infect* 27:813–16. <https://doi.org/10.1016/j.cmi.2020.12.030>
  98. Rodriguez JY, Le Pape P, Lopez O, Esquea K, Labiosa AL, Alvarez-Moreno C. *Candida auris*: a latent threat to critically ill patients with COVID-19. *Clin Infect Dis* 2020; published online Oct 18. <https://doi.org/10.1093/cid/ciaa1595>
  99. Arastehfar A, Shaban T, Zarrinfar H, Roudbary M, Ghazanfari M, Hedayati M-T et al (2021) Candidemia among Iranian patients with severe COVID-19 admitted to ICUs. *J Fungi* 7:280. <https://doi.org/10.3390/jof7040280>
  100. de Almeida JN, Moreno J, Francisco L, Noronha Marques EC, Mendes G, Barberino AV et al (2021) *Trichosporon asahii* superinfections in critically ill COVID-19 patients overexposed to antimicrobials and corticosteroids. *Mycoses*. <https://doi.org/10.1111/myc.13333>
  101. Passerini M, Terzi R, Piscaglia M, Passerini S, Piconi S (2020) Disseminated cryptococcosis in a patient with metastatic prostate cancer who died in the coronavirus disease 2019 (COVID-19) outbreak. *Cureus* 12:e8254. <https://doi.org/10.7759/cureus.8254>
  102. Cafardi J, Haas D, Lamarre T, Feinberg J. (2021) Opportunistic fungal infection associated with COVID-19. *Open Forum Infect Dis*: ofab016. <https://doi.org/10.1093/ofid/ofab016>
  103. Ventoulis I, Sarmourli T, Amoiridou P, Mantzana P, Exindari M, Gioula G et al (2020) Bloodstream infection by *Saccharomyces cerevisiae* in two COVID-19 patients after receiving supplementation of *Saccharomyces* in the ICU. *J Fungi* 6:98. <https://doi.org/10.3390/jof6030098>
  104. Chang CC, Senining R, Kim J, Goyal R (2020) An acute pulmonary coccidioidomycosis coinfection in a patient presenting with multifocal pneumonia with COVID-19. *J Investig Med high impact case reports* 8:2324709620972244. <https://doi.org/10.1177/2324709620972244>
  105. Shah AS, Heidari A, Civelli VF, Sharma R, Clark CS, Munoz AD et al (2020) The coincidence of 2 epidemics, coccidioidomycosis and SARS-CoV-2: a case report. *J Investig Med high impact case reports* 8:2324709620930540. <https://doi.org/10.1177/2324709620930540>
  106. de Macedo PM, Freitas DFS, Varon AG, da Cruz LC, Fonseca Ferreira LC, d'Avila Freitas A et al (2020) COVID-19 and acute juvenile paracoccidioidomycosis coinfection. *PLoS Negl Trop Dis* 14:e0008559. <https://doi.org/10.1371/journal.pntd.0008559>
  107. Bertolini M, Mutti MF, Barletta JA, Falak A, Cuatz D, Sisto A et al (2020) COVID-19 associated with AIDS-related disseminated histoplasmosis: a case report. *Int J STD AIDS* 31:1222–1224. <https://doi.org/10.1177/0956462420957518>
  108. Basso RP, Poester VR, Benelli JL, Stevens DA, Zogbi HE, da S Vasconcellos IC, et al. COVID-19-associated histoplasmosis in an AIDS Patient. *Mycopathologia* 2021;186:109–12. <https://doi.org/10.1007/s11046-020-00505-1>



109. Messina FA, Marin E, Caceres DH, Romero M, Depardo R, Priarone MM et al (2020) Coronavirus disease 2019 (COVID-19) in a patient with disseminated histoplasmosis and HIV—a case report from Argentina and literature review. *J Fungi* 6:275. <https://doi.org/10.3390/jof6040275>
110. Mang S, Kaddu-Mulindwa D, Metz C, Becker A, Seiler F, Smola S et al (2021) *Pneumocystis jirovecii* pneumonia and severe acute respiratory syndrome coronavirus 2 coinfection in a patient with newly diagnosed HIV-1 infection. *Clin Infect Dis* 72:1487–1489. <https://doi.org/10.1093/cid/ciaa906>
111. Menon AA, Berg DD, Brea EJ et al (2020) A case of COVID-19 and *Pneumocystis jirovecii* coinfection. *Am J Respir Crit Care Med* 202:136–138. <https://doi.org/10.1164/rccm.202003-0766LE>
112. Poignon C, Blaize M, Vezinet C, Lampros A, Monsel A, Fekkar A (2020) Invasive pulmonary fusariosis in an immunocompetent critically ill patient with severe COVID-19. *Clin Microbiol Infect* 26:1582–1584. <https://doi.org/10.1016/j.cmi.2020.06.026>
113. Khan N, Gutierrez CG, Martinez DV, Proud KC (2020) A case report of COVID-19 associated pulmonary mucormycosis. *Arch Clin Cases* 07:46–51. <https://doi.org/10.22551/2020.28.0703.10172>
114. Johnson AK, Ghazarian Z, Cendrowski KD, Persichino JG (2021) Pulmonary aspergillosis and mucormycosis in a patient with COVID-19. *Med Mycol Case Rep* 32:64–67. <https://doi.org/10.1016/j.mmcr.2021.03.006>
115. Bellanger A-P, Navellou J-C, Lepiller Q, et al. Mixed mold infection with *Aspergillus fumigatus* and *Rhizopus microsporus* in a severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) patient. *Infect Dis now* 2021; published online Jan 27. <https://doi.org/10.1016/j.idnow.2021.01.010>
116. Abdalla S, Almaslamani MA, Hashim SM, Ibrahim AS, Omrani AS (2020) Fatal coronavirus disease 2019-associated pulmonary aspergillosis; a report of two cases and review of the literature. *ID Cases* 22:e00935. <https://doi.org/10.1016/j.idcr.2020.e00935>
117. Yin CH, Wang C, Tang Z, Zhang SW, Wang BS (2004) Clinical analysis of 146 patients with critical severe acute respiratory syndrome in Beijing areas. *Clin J Emerg Med* 1:12–14
118. Thevissen K, Jacobs C, Holtappels M, Toda M, Verweij P, Wauters J (2020) International survey on influenza-associated pulmonary aspergillosis (IAPA) in intensive care units: responses suggest low awareness and potential underdiagnosis outside Europe. *Crit Care* 24:84. <https://doi.org/10.1186/s13054-020-2808-8>
119. Jenks JD, Hoenigl M (2018) Treatment of aspergillosis *J Fungi* 4:98. <https://doi.org/10.3390/jof4030098>
120. Fekkar A, Poignon C, Blaize M, Lampros A (2020) Fungal infection during COVID-19: Does *Aspergillus* mean secondary invasive aspergillosis? *Am J Respir Crit Care Med* 202:902–903. <https://doi.org/10.1164/rccm.202005-1945LE>
121. de León-Borrás R, DelPilar-Morales E, Rivera-Pérez N, Pal-lens-Feliciano M, Tirado-Gómez M, González-Sepúlveda L, et al. Factors associated to invasive fungal infection in hispanic patients with hematological malignancies. *Bol Asoc Med P R* 2017;109:43–8
122. Jolobe OM (2020) Air leaks, pneumatoceles, and air spaces in COVID-19 pneumonia. *Am J Emerg Med* 2020:30792. <https://doi.org/10.1016/j.ajem.2020.08.098>
123. Issara-Amphorn J, Surawut S, Worasilchai N, Thim-uam A, Finkelman M, Chindamporn A et al (2018) The synergy of endotoxin and (1→3)-β-D-glucan, from gut translocation, worsens sepsis severity in a lupus model of Fc gamma receptor IIb-deficient mice. *J Innate Immun* 10:189–201. <https://doi.org/10.1159/000486321>
124. Kullberg BJ, Arendrup MC (2015) Invasive candidiasis. *N Engl J Med* 373:1445–1456. <https://doi.org/10.1056/NEJMra1315399>
125. Marra AR, Camargo LFA, Pignatari ACC, Sukiennik T, Petersen Behar PR, Servolo Medeiros EA et al (2011) Nosocomial bloodstream infections in Brazilian hospitals: analysis of 2,563 cases from a prospective nationwide surveillance study. *J Clin Microbiol* 49:1866–1871. <https://doi.org/10.1128/JCM.00376-11>
126. Centers for Disease Control and Prevention. <https://www.cdc.gov/fungal/candida-auris/c-auris-antifungal.html> [Accessed 24 June 2021]
127. Gasparoto TH, de Oliveira CE, Vieira NA, Porto VC, Gasparoto CT, Campanelli AP et al (2012) The pattern recognition receptors expressed on neutrophils and the associated cytokine profile from different aged patients with *Candida*-related denture stomatitis. *Exp Gerontol* 47:741–748. <https://doi.org/10.1016/j.exger.2012.07.003>
128. Marteau PR, de Vrese M, Cellier CJ, Schrezenmeier J (2001) Protection from gastrointestinal diseases with the use of probiotics. *Am J Clin Nutr* 73:430S–436S. <https://doi.org/10.1093/ajcn/73.2.430S>
129. Erener S (2020) Diabetes, infection risk and COVID-19. *Mol Metab* 39:101044. <https://doi.org/10.1016/j.molmet.2020.101044>
130. Petrikos G, Tsioutis C (2018) Recent advances in the pathogenesis of mucormycoses. *Clin Ther* 40:894–902. <https://doi.org/10.1016/j.clinthera.2018.03.009>
131. Morales-Franco B, Nava-Villalba M, Medina-Guerrero EO, Sánchez-Nuño YA, Davila-Villa P, Anaya-Ambriz EJ, et al. Host-pathogen molecular factors contribute to the pathogenesis of *Rhizopus* spp. in diabetes mellitus. *Curr Trop Med reports* 2021;8:6–17. <https://doi.org/10.1007/s40475-020-00222-1>
132. Thomas CF, Limper AH (2004) *Pneumocystis* pneumonia. *N Engl J Med* 350:2487–2498. <https://doi.org/10.1056/NEJMr a032588>
133. Vizcarra P, Pérez-Elías MJ, Quereda C, Moreno A, Vivancos MJ, Drona F et al (2020) Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort. *Lancet HIV* 7:e554–e564. [https://doi.org/10.1016/S2352-3018\(20\)30164-8](https://doi.org/10.1016/S2352-3018(20)30164-8)
134. Xu Z, Zhang C, Wang F-S (2020) COVID-19 in people with HIV. *Lancet HIV* 7:e524–e526. [https://doi.org/10.1016/S2352-3018\(20\)30163-6](https://doi.org/10.1016/S2352-3018(20)30163-6)

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.